Chronic Idiopathic Urticaria

The HCPLive chronic idiopathic urticaria page is a comprehensive resource for clinical news and insights on CIU. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

COVID-19 Linked to Exacerbations in Skin Diseases

September 15, 2021

Article

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

Ligelizumab and Omalizumab Optimal Treatments for Chronic Spontaneous Urticaria

August 26, 2021

Article

Investigators believe their study shows the efficacy and safety of the 2 biologic agents, which are known to have anti-inflammatory and immunosuppressant qualities.

Ligelizumab Superior to Omalizumab for Chronic Spontaneous Urticaria Clearance

April 25, 2021

Article

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.

FDA Allows for Omalizumab Self-Injection Across All Indications

April 12, 2021

Article

The approval of the sBLA means greater flexibility and reduced barriers in care during the pandemic.

FDA Sends Warning Letters for Illegal CBD Products

December 22, 2020

Article

The 5 companies issued letters will have 15 days to submit a compliance plan.

Orphan No More: A New Momentum for Pediatric Dermatology

December 16, 2020

Article

The FDA approvals of biologics for atopic dermatitis and psoriasis have ushered in a new era for the once-stagnant field of pediatric dermatology.

FDA Approves Topical Treatment for Actinic Keratosis

December 15, 2020

Article

Approval allows Almirall to move forward with the topical ointment for individuals with AK on the face or scalp.

New Data Suggests Upadacitinib Superior to Dupilumab for Atopic Dermatitis

December 10, 2020

Article

In new phase 3b findings, a greater proportion of patients treated with upadacitinib achieved EASI 75 at week 16 than those who received dupilumab.

Lower Treatment Effectiveness for Secukinumab, Ustekinumab in Real-World Setting

December 03, 2020

Article

There is a gap between the efficacy of biologics in trials and the real-world setting.

Psoriasis Flare Rates Low Among Systemic Corticosteroid Users

December 01, 2020

Article

Strict avoidance of systemic corticosteroids among patients with psoriasis may be unnecessary.